Seeking Alpha

MJack1

MJack1
Send Message
View as an RSS Feed
View MJack1's Comments BY TICKER:
Latest  |  Highest rated
  • INVIVO PREPARED FOR NATIONAL NETWORK TELEVISION SOON [View instapost]
    The author is "long" 700 shares but is probably going to sell after a run-up? Really? I am long 40,000 shares and don't plan to sell a significant number of them for some years. That's what "long" is. The scaffold (NSS) and it's nextgen sibling the NSS+ bioengineered tissue will come to market and the stock could eventually go 10X by then. Only traders would sell this stock after a mere news feature.

    Yes, this will be a disruptive biotech in the newly emerging genre of biomaterials. Whatever appreciation it gets from the greater exposure that a national show brings is nothing compared to an assortment of future catalysts that will be coming.
    May 31, 2015. 09:56 PM | Likes Like |Link to Comment
  • InVivo Revolutionizing Spinal Cord Injury [View article]
    Hello Jason,
    Do you intend to research the new EAP pathway and how that could be of significant benefit to InVivo? I am expecting that it would further shorten time to market on up-coming products.
    Apr 15, 2015. 11:48 PM | Likes Like |Link to Comment
  • InVivo Therapeutics: Time To Double Down [View article]
    biostothemoon, not sure if you finished your reading assignment suggested by cmcfarling, but I would also suggest you refrain in the future from writing such intellectually dishonest comments as you have here.
    Apr 14, 2015. 09:55 PM | 4 Likes Like |Link to Comment
  • InVivo Revolutionizing Spinal Cord Injury [View article]
    Just thinking that InVivo will have multiple sources to shop this and it is to any stem cell co's future benefit to work together with them. Whoever emerges there would reap the benefit. Could InVivo do their bio-engineered tissue without a third party stem cell co?

    I'm curious when you say applicable to all spinal cord injuries, would you draw any lines? I'd think certainly all non-penetrating thoracic for sure, including the incompletes. Possibly they could include penetrating, but not a complete sever?

    As far as cervical, that would venture into potentially dangerous uncharted waters, no? But even with these caveats, there would seem to be a nice amount of hypothetical up-side beyond HDE and before chronics.
    Mar 30, 2015. 06:59 PM | 1 Like Like |Link to Comment
  • InVivo Revolutionizing Spinal Cord Injury [View article]
    Jason, I believe you are correct on the marriage of the two approaches. It appears the NSS works well because of the efficiency of its mechanism of function. Unfortunately that same efficiency and yield does not appear with these CUR "self-grafting" cells. Combined together could be a holy grail.
    Mar 29, 2015. 05:44 PM | 1 Like Like |Link to Comment
  • InVivo Revolutionizing Spinal Cord Injury [View article]
    Glad this wasn't about the "p-value" LOL.
    Mar 28, 2015. 09:05 PM | 1 Like Like |Link to Comment
  • InVivo Revolutionizing Spinal Cord Injury [View article]
    Great questions White Knight, and I would love to hear Jason's well-considered replies.
    Mar 28, 2015. 11:47 AM | 1 Like Like |Link to Comment
  • InVivo's Day Has Arrived [View article]
    Hi Jason,
    Your reply to yzz was also helpful for me since I'm also not in the financial industry. I've not accused you, but I am still puzzled how the people directly involved with these deals can apparently trade on certain inside information. It does not seem very fair.

    Bio makes that point above very well. Can't these funding events take place more behind the scenes? I don't understand how a temporary low priced buy should affect the usual share price range for very long. We should be down at most by the dilution factor. At best we should be higher than that because the cash issue was repaired. One less problem going forward and everything else remains the same or is even closer to showtime.
    May 9, 2014. 12:35 PM | 1 Like Like |Link to Comment
  • InVivo's Day Has Arrived [View article]
    Hello Jason. I don't wish to be combative here:

    I just re-read your article and nowhere do I see you state a $2.00 target, nor do you recommend a hold.

    However you clearly state: "The Neuro-Spinal Scaffold in the HUD population easily looks like a $500-million device. If that's the case, InVivo's stock is certainly very attractive at a market capitalization of only $145 million today."

    Nobody needs to fudge any numbers. "TODAY" implies present tense, ie. the day you wrote the article. As does, InVivo's stock "IS" certainly very attractive at a market capitalization of "ONLY" $145 million today.

    You cannot back peddle. Your words are crystal clear, spoken in the present tense, and use adjectives such as "VERY" attractive and "ONLY" $145 million. Where is the intellectual honesty in your most recent comments then?

    Sorry though for my error using $200M instead of $145M in the numerator (was thinking of recent valuation before those issues came out and as you say are now quashed) but even still that comes to $1.86 pps which is still 71 cents higher than $1.15 and is as you stated "very attractive" merely a week ago before the cash problem was resolved.
    May 8, 2014. 02:42 PM | Likes Like |Link to Comment
  • InVivo's Day Has Arrived [View article]
    Sorry but I have to agree with Bioinformed. He reminds us of Jason's own words to which he cannot backpeddle:

    "The Neuro-Spinal Scaffold in the HUD population easily looks like a $500-million device. If that's the case, InVivo's stock is certainly very attractive at a market capitalization of only $145 million today."

    That would equate with a PPS of $2.56 in real time the day he published those remarks merely a week ago. So a target of $4 which was also the latest that I remember seeing as well, makes sense considering if the clinicals go well (highly expected, btw due to the low bar primarily being safety), a target of $4 up from $2.56 is well within reasonable expectation.

    There is no credible creative backpeddling that Jason can possibly come up with. He was clearly called out here.
    May 8, 2014. 01:29 PM | 1 Like Like |Link to Comment
  • InVivo's Day Has Arrived [View article]
    Hello Jason,

    I'd be curious as to your thoughts on the best way the company should proceed with a cash injection. I am EXTREMELY disappointed so far with where the share price has gone even after encouraging news. It needs to rise considerably before any offering (ie: at least another dollar), and should not have dropped as it has on Friday 5/2 and continuing today.

    Management MUST do something to mitigate this!
    May 5, 2014. 12:51 PM | Likes Like |Link to Comment
  • InVivo Therapeutics Suffers From FDA's Timidity On Biologic Grafts [View article]
    Current price is from shorts manipulation (probably illegal). It will be great when a strong positive PR comes out because then there will be a short squeeze and the MM's will (and rightfully SHOULD) gap it up to compensate for this bogus price drop. Napodano has very realistic pricing analysis and factors in better scenarios. Most importantly he does not factor in hydrogels at all. This (IMO) will be the secret weapon and will change everything.
    Sep 2, 2013. 01:32 AM | Likes Like |Link to Comment
  • InVivo slides as CEO resigns [View news story]
    It's not a pink sheet.
    Aug 25, 2013. 08:36 AM | Likes Like |Link to Comment
  • InVivo slides as CEO resigns [View news story]
    Probably. And I'm sure the SEC would like to know too.
    Aug 25, 2013. 08:34 AM | Likes Like |Link to Comment
  • InVivo Therapeutics: A Reality Distortion Field [View article]
    Conveniently, he doesn't answer.
    Aug 25, 2013. 08:22 AM | Likes Like |Link to Comment
COMMENTS STATS
26 Comments
26 Likes